SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    E J Brandl, A K Tiwari, X Zhou, J Deluce, J L Kennedy, D J Müller, M A Richter, Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder, The Pharmacogenomics Journal, 2014, 14, 2, 176

    CrossRef

  2. 2
    Ewa Mörtberg, Gerhard Andersson, Predictors of response to individual and group cognitive behaviour therapy of social phobia, Psychology and Psychotherapy: Theory, Research and Practice, 2014, 87, 1
  3. You have free access to this content3
    Toshi A. Furukawa, Yumi Nakano, Tadashi Funayama, Sei Ogawa, Tetsuji Ietsugu, Yumiko Noda, Junwen Chen, Norio Watanabe, Tatsuo Akechi, Cognitive–behavioral therapy modifies the naturalistic course of social anxiety disorder: Findings from an ABA design study in routine clinical practices, Psychiatry and Clinical Neurosciences, 2013, 67, 3
  4. 4
    B.D. Karrenbauer, C.P. Müller, Y.J. Ho, R. Spanagel, J.P. Huston, R.K.W. Schwarting, C.R. Pawlak, Time-dependent in-vivo effects of interleukin-2 on neurotransmitters in various cortices: Relationships with depressive-related and anxiety-like behaviour, Journal of Neuroimmunology, 2011, 237, 1-2, 23

    CrossRef

  5. 5
    Peter P. Zandi, Jennifer T. Judy, The Promise and Reality of Pharmacogenetics in Psychiatry, Clinics in Laboratory Medicine, 2010, 30, 4, 931

    CrossRef

  6. 6
    Peter P. Zandi, Jennifer T. Judy, The Promise and Reality of Pharmacogenetics in Psychiatry, Psychiatric Clinics of North America, 2010, 33, 1, 181

    CrossRef

  7. 7
    Richard A. Hansen, Bradley N. Gaynes, Gerald Gartlehner, Charity G. Moore, Ruchi Tiwari, Kathleen N. Lohr, Efficacy and tolerability of second-generation antidepressants in social anxiety disorder, International Clinical Psychopharmacology, 2008, 23, 3, 170

    CrossRef

  8. 8
    Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors, Genetics in Medicine, 2007, 9, 12, 819

    CrossRef

  9. 9
    Mugdha Thakur, Iris Grossman, Douglas C McCrory, Lori A Orlando, David C Steffens, Kathryn E Cline, Rebecca N Gray, Jennifer Farmer, Georgette Dejesus, Cara O'Brien, Gregory Samsa, David B Goldstein, David B Matchar, Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors, Genetics in Medicine, 2007, 9, 12, 826

    CrossRef

  10. 10
    Spilios V. Argyropoulos, Sean D. Hood, Mariona Adrover, Caroline J. Bell, Ann S. Rich, Jon R. Nash, Neil C. Rich, Harry J. Witchel, David J. Nutt, Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder, Biological Psychiatry, 2004, 56, 7, 503

    CrossRef

  11. 11
    Eric Hollander, Daniel M. Samons, Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomized controlled trial, Current Psychiatry Reports, 2003, 5, 4, 249

    CrossRef

  12. 12
    A. Pélissolo, C. André, H. Pujol, S. N. Yao, D. Servant, A. Braconnier, S. Orain-Pélissolo, S. Bouchez, J.-P. Lépine, Personality dimensions in social phobics with or without depression, Acta Psychiatrica Scandinavica, 2002, 105, 2
  13. 13
    Lisa A. Lampe, Social phobia: common, disabling and treatable, Current Opinion in Psychiatry, 2002, 15, 2, 169

    CrossRef